Astellas Pharma Inc. acquired Xyphos Biosciences, Inc. to strengthen its immuno-oncology pipeline. With the acquisition Astellas gains Xyphos’ novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as...
Astellas Pharma Inc. announced a nearly $13 million investment into two innovation incubators operated by LabCentral, a premier U.S.-based laboratory facility for next-generation biotech startups. Astellas has infused over $1 billion into the Boston-area life...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
